Decrease in brain glucose with elevated plasma glucose levels

1972 ◽  
Vol 81 (1) ◽  
pp. 185
Author(s):  
Jean Holowach Thurston
1973 ◽  
Vol 7 (8) ◽  
pp. 691-695 ◽  
Author(s):  
Jean Holowach-Thurston ◽  
Richard E Hauhart ◽  
Elizabeth M Jones ◽  
Maria G Ikossi ◽  
R Wendell Pierce

PLoS ONE ◽  
2012 ◽  
Vol 7 (5) ◽  
pp. e37787 ◽  
Author(s):  
Thomas Lundåsen ◽  
Eva-Marie Andersson ◽  
Michael Snaith ◽  
Helena Lindmark ◽  
Johanna Lundberg ◽  
...  

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Xu Xiao ◽  
Hong-jun Du ◽  
Wei-jian Hu ◽  
Peter X. Shaw

Objective. To observe the relationship between changes in renin-angiotensin-aldosterone system (RAAS) activity and blood plasma glucose after administration of hydrochlorothiazide (HCTZ) for one year in patients with hypertension.Methods. 108 hypertensive patients were given 12.5 mg HCTZ per day for one year. RAAS activity, plasma glucose levels, and other biochemical parameters, as well as plasma oxidized low density lipoprotein (oxLDL) levels, were measured and analyzed at baseline, six weeks, and one year after treatment.Results. After one year of treatment, the reduction in plasma glucose observed between the elevated plasma renin activity (PRA) group (-0.26±0.26 mmol/L) and the nonelevated PRA group (-1.36±0.23 mmol/L) was statistically significant (P<0.05). The decrease of plasma glucose in the elevated Ang II group (-0.17±0.18 mmol/L) compared to the nonelevated Ang II group (-1.07±0.21 mmol/L) was statistically significant (P<0.05). The proportion of patients with elevated plasma glucose in the elevated Ang II group (40.5%) was significantly higher than those in the nonelevated Ang II group (16.3%) (P<0.05). The relative oxLDL level was not affected by the treatment.Conclusions. Changes in RAAS activity were correlated with changes in plasma glucose levels after one year of HCTZ therapy.


1996 ◽  
Vol 16 (3) ◽  
pp. 439-449 ◽  
Author(s):  
Hajime Nakanishi ◽  
Nancy F. Cruz ◽  
Keiji Adachi ◽  
Louis Sokoloff ◽  
Gerald A. Dienel

The equilibrium brain/plasma distribution ratio for 3- O-methyl-D-glucose (methylglucose) varies with plasma and tissue glucose contents and can be used to determine local glucose levels in brain. This ratio was previously found to rise as brain glucose concentration fell in response to lowered plasma glucose content. The ratios, however, differed with the same tissue glucose levels in conscious and pentobarbital-sedated rats, suggesting that changes in metabolic demand might alter the quantitative relationship between the methylglucose distribution ratio and brain glucose concentration. To examine this possibility, metabolic rate was varied by focal drug application, and hexose concentrations measured in treated and surrounding tissue. When tissue glucose levels were reduced by raised metabolic demand, methylglucose distribution ratios also fell. When brain glucose levels rose due to reduced consumption, the methylglucose distribution ratio also rose. Thus, in contrast to the inverse relationship between brain/plasma methylglucose ratio and brain glucose concentration when brain glucose content is altered secondarily to changes in plasma glucose level, changes in brain glucose content induced by altered glucose utilization cause the brain glucose level and methylglucose distribution ratio to rise and fall in a direct relationship. Determination of brain glucose content from methylglucose distribution ratios must take into account rates of glucose delivery and consumption.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 772-P
Author(s):  
MARIKO HIGA ◽  
AYANA HASHIMOTO ◽  
MOE HAYASAKA ◽  
MAI HIJIKATA ◽  
AYAMI UEDA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document